Cat. #161921
SK-N-BE(2) Cell Line
Cat. #: 161921
Availability: 8-10 weeks
Organism: Human
Tissue: Brain
Model: Tumourigenic
£575.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: June L. Biedler
Institute: Memorial Sloan-Kettering Cancer Center (MSK)
Primary Citation: Biedler et al. 1976. Journal of the National Cancer Institute. 57: 683-695. PMID: 62055.
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: SK-N-BE(2) Cell Line
- Cancer: Neurological cancer
- Cancers detailed: Neuroblastoma
- Organism: Human
- Gender: Male
- Tissue: Brain
- Donor: This cell line was established in 1972 from a metastatic site (bone marrow) in a two-year-old Caucasian male with malignant neuroblastoma.
- Morphology: Neuroblast
- Growth properties: Mixed: adherent and suspension
- Model: Tumourigenic
- Model description: Tumourigenic; an inoculum of 107 cells produced tumours in cortisonised hamster cheek pouches with 18% frequency
- Products or characteristics of interest: Karyotype: modal number = 44; one or more HSR bearing chromosomes
- Description: SK-N-BE(2) is a neuroblastoma cell line that displays MYCN amplification. These cells have moderate dopamine-b-hydroxylase activity and low-choline acetyltransferase activity. The SK-N-BE(2) cells are known to form tumours in immunocompromised mice.
- Application: 3D cell culture Immunology Neuroscience
- Biosafety level: 1
- Additional notes: The cells exhibit moderate levels of dopamine beta hydroxylase activity. SK-N-BE(2) cells have a reported saturation density greater than 1 X 106 cells/cm2. The morphology of the cells varies with some cells having long processes and others that are epithelioid like. The cells will aggregate, form clumps and float.
Applications
- Application: 3D cell culture Immunology Neuroscience
Handling
- Growth medium: 1:1 mixture of EMEM:F12 Medium, then supplemented with FBS to a final concentration of 10%
- Temperature: 37° C
- Atmosphere: 5% CO2 in air
- Shipping conditions: Dry Ice
- Storage medium: Complete growth medium supplemented with 5% (v/v) DMSO
- Storage conditions: Vapor phase of liquid nitrogen
- Str profiling: Amelogenin: X,YCSF1PO: 10D13S317: 11D16S539: 9,11D5S818: 12D7S820: 9,10TH01: 6,7TPOX: 8,11vWA: 18D3S1358: 19D21S11: 30,31,32.2D18S51: 14,16Penta_E: 14,18Penta_D: 13,14D8S1179: 13,14FGA: 22,25D19S433: 12,13D2S1338: 17,23
References
- Barnes et al. 1981. In Vitro. 17: 619-131. PMID: 7327593.
- Biedler et al. 1976. Science. 191: 185-187. PMID: 942798.
- Biedler et al. 1978. Cancer Research. 38: 3751-3757. PMID: 29704.
